Skip to main content

Main menu

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Why we should care about ultra-rare disease

Sergio Harari
European Respiratory Review 2016 25: 101-103; DOI: 10.1183/16000617.0017-2016
Sergio Harari
U.O. di Pneumologia e Terapia Semi-Intensiva Respiratoria-Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare, Ospedale San Giuseppe-MultiMedica IRCCS, Milan, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sharari@hotmail.it
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Orphan drugs for patients with ultra-rare diseases: between cost-effectiveness and equality of access to cure http://ow.ly/Zlmf4

To date, more than 7000 rare diseases have been identified which affect 30–40 million patients in the European Union (EU), and some 250 new rare diseases are described every year [1, 2]. Primary or secondary lung involvement occurs in ∼5% of rare diseases; therefore, approximately 1–2 million people in the EU are likely to be affected by rare pulmonary diseases [3]. This means that if individuals suffering from rare diseases are by definition “uncommon”, rare conditions affect a very large number of people. Arguably, in the past few years interest in rare diseases has grown, as demonstrated by the agendas of politicians and health authorities, but too little attention is still paid to ultra-rare diseases. Although no legal definition of an “ultra-rare” disease has yet been established, this subcategory was introduced by the National Institute for Health and Care Excellence for drugs with indications for diseases that have a prevalence of <1 per 50 000 persons [4–6]. According to EU legislation, patients suffering from a rare condition are entitled to the same standard of care as other patients [7]. In some European countries, such as Italy and the Netherlands, the right to healthcare is protected constitutionally and everyone is entitled to equal access to public healthcare [8]. Moreover, article two of the European Convention on Human Rights (ECHR) states that “Everyone's right to life shall be protected by law” [9].

Also for these reasons, European legislation was introduced in 2000 to drive the development of orphan drugs, arriving much later than the USA Orphan Drug Act of 1983. This legislation requires that the pharmaceutical industry has a right to: 1) obtain protocol assistance at a reduced rate; 2) access the centralised authorisation procedure; 3) enjoy lower registration fees; and 4) benefit from 10 years of market exclusivity after registration [7, 10–12]. This has led to the authorisation by the European Medicines Agency of 124 new orphan drugs in the EU between 2000 and 2015, of which about one-third were for ultra-rare diseases (www.ema.europa.eu/ema/). .

In the respiratory field, there are several ultra-rare diseases: lymphangiomatosis [13], pleuro-parenchymal fibroelasytosis, pulmonary alveolar microlithiasis [14], ataxia telangiectasia [15], pulmonary alveolar proteinosis, lysosomal storage diseases, pulmonary dendriform ossification, light chain deposition disorders [16], Birt–Hogg–Dubè syndrome [16], rare vascular disorders and vasculitis along with several others.

The research and development process for new drugs to treat very rare diseases requires significant investment and the allocation of highly sophisticated resources, a situation which raises ethical as well as social issues. It is indeed fair to wonder whether society and the public at large should bear the high cost of research activities benefitting a very small number of individuals, albeit affected by severe and chronic ailments, or whether this goes against the principle of equality. Strangely, patients with rare and, at times, unknown conditions tend to absorb even higher resources than patients affected by more common diseases generally described as “normal”.

As stated by Huges et al. [5], the principle of equality would argue against special consideration being given to patients with rare conditions in the allocation of healthcare resources. Investing substantial amounts of resources in rare conditions may be viewed as unethical from a utilitarian point of view, as it does not maximise the benefits for society as a whole [5]. But who should take care of this, if not the government?

A key factor underlying the failure of many orphan drugs to meet proposed standards for cost-effective­ness is that manufacturers need to generate revenues to allow them to recoup research and development expenditures for a small group of patients. This challenge inevitably leads to elevated acquisition costs.

For EU member states to make decisions on reimbursement, it is crucial to acquire greater insights into the balance between expenses and health gains for a specific drug, in order to determine the “value for money” for orphan drugs. Conversely, the public does not seem prepared to deny patients treatment merely on the basis of cost [17]. Accordingly, drug acquisition costs are inversely correlated with prevalence.

However, despite high costs and considering the rarity of these diseases, the outlay for these drugs represents only a small proportion of the global drug budget of a modern European healthcare system.

Another important issue is how research should be carried out for ultra-rare diseases, along with the issue of quality. Clinical evidence on ultra-rare drugs for chronic diseases is frequently based on observations among small numbers of patients in short-term studies utilising surrogate outcomes rather than long-term trials [18]. Typically, in such studies, the primary end-points are surrogate; the relationship between the surrogate end-point and survival or mortality or other clinically relevant end-points is not always clear [18]. For example, improved walking distance induced by drugs affecting pulmonary arterial hypertension, although statistically significant, is of questionable clinical relevance. The efficacy of anti-cancer drugs has been measured in terms of tumour response or time-to-progression rather than survival or quality of life. Joppi et al. [18] report that in some cases the trial was too short with respect to the natural history of the rare disease evaluated: 20 weeks for agalsidase-β or 18 months for agalsidase-α in the treatment of Fabry disease; 12 weeks for pegvisomant acting on resistant acromegaly and also for drugs that are active in pulmonary hypertension or epilepsy.

However, although less stringent criteria may be adopted for orphan drugs than for common drugs, this should not be a good reason not to guarantee the best available treatment to patients with rare diseases [18]. A critical step in generating data is to establish disease-specific registries including longitudinal data on all affected patients. Schuller et al. [12] suggest that ideally registries would start before drugs are marketed, so as to produce data about the natural history of the disease. Accordingly, EU countries need to work in close cooperation.

Organising care for individuals with ultra-rare conditions demands a different and highly specific approach. Recent research has shown that a well-organised, patient-centred, multidisciplinary approach is more patient friendly and generates better outcomes than the current care model [19].

National governments must develop strategies to drive clinical research, and incentives to encourage teaching hospitals to care for and investigate rare and ultra-rare diseases. Major efforts are also needed to train specialists with enough expertise to promptly recognise ultra-rare diseases, explore differential diagnoses and offer the most advanced treatment options. All this will be facilitated by supra-national partnerships between the few specialists with an interest in specific conditions, ranging from the establishment of rare diseases registries (to significantly increase patient populations) to web-based options (extremely fast contacts and real-time data sharing thanks to teleconsultations that also permit contacts among patients) [20]. Rare and ultra-rare conditions represent a major research challenge since they highlight and amplify the need for cooperation and sharing of know-how on the one hand, and for channelling efforts towards dedicated centres of excellence to develop and offer multidisciplinary skills on the other. Is this a challenge that can be met?

Footnotes

  • Conflict of interest: Disclosures can be found alongside the online version of this article at err.ersjournals.com

  • Provenance: Submitted article, peer reviewed.

  • Received February 26, 2016.
  • Accepted March 8, 2016.
  • Copyright ©ERS 2016.

ERR articles are open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.

References

  1. ↵
    OrphaNet. www.orpha.net/consor/cgi-bin/index.php?lng=EN Date last updated: March 10, 2016. Date last accessed: May, 2015.
  2. ↵
    1. Wastfelt M,
    2. Fadeel B,
    3. Henter JI
    . A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med 2006; 260: 1–10.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Harari S,
    2. Lau EM,
    3. Tamura Y, et al.
    Rare (pulmonary) disease day: “feeding the breath, energy for life!” Eur Respir J 2015; 45: 297–300.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    National Institute for Clinical Excellence. NICE Citizens Council Report Ultra Orphan Drugs. London, NICE, 2004.
  5. ↵
    1. Huges DA,
    2. Tunnage B,
    3. Yeo ST
    . Drugs for exceptionally rare diseases: do they deserve special status for funding? Q J Med 2005; 98: 829–836.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    NICE. Appraising orphan drugs [updated 14 April 2008]. National Institute for Health and Care Excellence. London, UK, 2008.
  7. ↵
    European Parliament, Council of the European Union. Regulation (EC) No 141/2000 of the European Parliament and the Council of 16 December 1999 on orphan medicinal products. Off J Eur Commun 2000; L18: 1–5.
    OpenUrl
  8. ↵
    1. Den Exter A,
    2. Hermans H
    1. Den Exter A,
    2. Hermans H
    . The right to health care: a changing concept? In: Den Exter A, Hermans H, eds. The Right to Health Care in Several European Countries. The Hague, Kluwer Law International, 1999; pp. 1–10.
  9. ↵
    European Court of Human Rights. Convention for the Protection of Human Rights and Fundamental Freedoms. Strasbourg, European Court of Human Rights, 1950.
  10. ↵
    European Medicines Agency. Orphan incentives. www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000393.jsp Date last accessed: May, 2015.
  11. The European Agency for the Evaluation of Medicinal Products. Report on the first 3-year mandate of the committee for orphan medicinal products (COMP). London, EMEA, 2003.
  12. ↵
    1. Schuller Y,
    2. Hollak CE,
    3. Biegstraaten M
    . The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review. Orphanet J Rare Dis 2015; 10: 92.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Luisi F,
    2. Torre O,
    3. Harari S
    . Thoracic involvement in generalised lymphatic anomaly. Eur Respir Rev 2016; 25: 170–177.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Castellana G,
    2. Castellana G,
    3. Gentile M, et al.
    Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide. Eur Respir Rev 2015; 24: 607–620.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Bhatt JM,
    2. Bush A,
    3. van Gerven M, et al.
    ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev 2015; 24: 565–581.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Ferreira Francisco FA,
    2. Soares Souza A Jr.,
    3. Zanetti G, et al.
    Multiple cystic lung disease. Eur Respir Rev 2015; 24: 552–564.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Schlander M,
    2. Garattini S,
    3. Holm S, et al.
    Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res 2014; 3: 399–422.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Joppi R,
    2. Bertele V,
    3. Garattini S
    . Orphan drug development is not taking off. Br J Clin Pharmacol 2009; 67: 494–502.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Van Groenendael S,
    2. Giacovazzi L,
    3. Davison F, et al.
    High quality, patient centred and coordinated care for Alstrom syndrome: a model of care for an ultra-rare disease. Orphanet J Rare Dis 2015; 10: 149.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Hennekam RC
    . Care for patients with ultra-rare disorders. Eur J Med Genet 2011; 54: 220–224.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 25 Issue 140 Table of Contents
European Respiratory Review: 25 (140)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Why we should care about ultra-rare disease
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Why we should care about ultra-rare disease
Sergio Harari
European Respiratory Review Jun 2016, 25 (140) 101-103; DOI: 10.1183/16000617.0017-2016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Why we should care about ultra-rare disease
Sergio Harari
European Respiratory Review Jun 2016, 25 (140) 101-103; DOI: 10.1183/16000617.0017-2016
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • The flare of care for rare: per aspera ad astra for rare lung diseases!
  • Respiratory infections
  • 9th International Meeting on Pulmonary Rare Diseases and Orphan Drugs
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERR

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising
  • Sponsorship

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN: 0905-9180
Online ISSN: 1600-0617

Copyright © 2023 by the European Respiratory Society